When it comes to Active Surveillance (AS) decisions, there’s good news and bad news. The good news: based on biopsy results, more doctors are recommending AS for prostate cancer (PCa) patients with insignificant disease. The bad news: the biopsy might have missed significant PCa so the patient can’t know for sure if AS is a keep reading
It is always gratifying for a doctor when something he or she wholeheartedly believes in gets affirmed by published research. For me, this is the case with a new Italian study, “The Roles of Multiparametric MRI, PCA3, and PHI: Which Is The Best Predictor of Prostate Cancer After a Negative Biopsy?”[i] The authors recognize the keep reading
By: Dan Sperling, M.D. In 2009, an article on the single-cell theory of prostate cancer metastasis appeared in the journal Nature. There was little fanfare, but it might have been better met with a trumpeted announcement. Why? Because it supported the theory that some prostate cancer cells are more lethal than others—and this has tremendous keep reading
One of the most respected U.S. urologists is Dr. E. David Crawford, Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He gave a presentation to the plenary session of the recent European Association of Urology meeting in Madrid, on the keep reading
If you’re like most men age 40+, you probably get your PSA (prostate specific antigen) test when you go for a physical that includes a blood draw. You learned either from your doctor, or a health promotion, that men should get a baseline PSA at age 45 (40 if you have known risk factors) and keep reading